SPY334.57+0.24 0.07%
DIA274.62+0.72 0.26%
IXIC11,010.98-97.09 -0.87%

Neovasc Reports Its Reducer System Featured In Supplement In Germany's Second Largest National Newspaper, 'Frankfurter Allgemeine Zeitung'

Neovasc, Inc. (“Neovasc” or the “Company”) ((NASDAQ, TSX:NVCN) announced today that the Neovasc Reducer™ (the “Reducer”) was featured in a supplement titled:

Benzinga · -

Neovasc, Inc. (“Neovasc” or the “Company”) ((NASDAQ, TSX:NVCN) announced today that the Neovasc Reducer™ (the “Reducer”) was featured in a supplement titled: “Volkskrankheiten” or “Common Diseases” in Frankfurter Allgemeine Zeitung(FAZ), the second largest national newspaper by circulation in Germany. The supplement will be mailed to subscribers, reaching an estimated audience of almost 500,000 and should be available in the waiting areas of physician offices across Germany over the coming months.  

A portion of the 20-page supplement is dedicated to educating readers on Angina Pectoris, a common form of debilitating chronic chest pain. In the first part of the article, Dr. Sebastian Philipp from the Elbe Clinics in Stade, and Professor Ulrich Schäfer from the Marienkrankenhaus in Hamburg, explain how the Reducer, which has been available in Germany for four years, provides a complementary therapy that  should be used when patients have exhausted anti-anginal therapy yet are still symptomatic. Prof. Schäfer explains how the Reducer, once in place, can take between six to eight weeks to improve blood flow.  As the patient improves, Prof. Schäfer recommends patients consider taking up or continuing sporting activities such as biking, running, hiking and swimming at a lower intensity to improve their health.

Prof. Dr. Tommaso Gori, who leads the cardiac catheterization lab at the prestigious University Hospital Mainz, is featured in the supplement explaining how the Reducer therapy can help patients with Chronic Angina Pectoris. Professor Gori commented on the available robust clinical evidence on the safety and efficacy of Reducer therapy and highlighted that, according to the best research to date, 75% of patients treated with Reducer feel better and experience less chest pain.

Fred Colen, President and Chief Executive Officer of Neovasc, stated, “We are pleased that three prominent leaders in heart disease have indicated that the use of Reducer is a welcomed alternative for patients who are suffering from refractory angina, a severely debilitating condition that affects millions worldwide.  The Reducer has been included as a treatment option for refractory angina by the European Society of Cardiology Practice Guidelines, and we believe the special supplement in Frankfurter Allgemeine Zeitungwill help educate many in Germany on how the Reducer can offer a solution for those suffering from angina.”